This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Inflammation	Complement receptor 3 (CR3; CD11b)	<i>In vitro</i> and mouse studies suggest that activating CD11b could help treat inflammatory disease. <i>Cd11b</i> ^{-/-} mice challenged with <i>Escherichia coli</i> had greater mortality, sepsis and shock than challenged wild-type or <i>Cd11b</i> ^{+/-} mice. In human <i>CD11b</i> ^{-/-} macrophages, lipopolysaccharide (LPS)-triggered inflammatory responses were greater than those in wild-type or <i>CD11b</i> ^{+/-} cells. Next steps include identifying activators of CD11b. SciBX 3(29); doi:10.1038/scibx.2010.898 Published online July 29, 2010	Patent application filed for inflammation indications; available for licensing in China	Han, C. <i>et al. Nat. Immunol.</i> ; published online July 18, 2010; doi:10.1038/ni.1908 Contact: Xuetao Cao, Second Military Medical University, Shanghai, China e-mail: caoxt@immunol.org